I was not about to mention a CR but there has been a previous pattern of behaviour by Bard1. The company is now top heavy after the merger, there is a lot of technical staff to support and much exciting work to complete. Best to ensure funding to keep this work going with such promise at hand.
Ann: Outstanding SubB2M Ovarian Cancer Test Data, page-361
-
- There are more pages in this discussion • 172 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
58.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $63.96M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 450 | 57.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 58.0¢ | 13111 | 1 |
View Market Depth
| Last trade - 07.00am 15/07/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |
Day chart unavailable